| PIPELINE | Target Validation | Lead Optimization | IND-Enabling | Phase I | Phase II | Phase III |
|---|---|---|---|---|---|---|
AtrasentanlgA nephropathy and other proteinuricglomerular diseases |
|
|||||
BION-1301lgA nephropathy |
|
|||||
400-883-0816
info@sanreno.com
Shanghai ● Beijing, China
© 2022 SanReno. All Rights Reserved Terms of UsePrivacy Policy
简体中文
